Buy Now
Psoriasis Drugs Market Size, Share, Growth & Industry Analysis, By Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, Others), By Treatment (Topical, Systemic, Biologics,), By Route of Administration (Oral, Parenteral), and Regional Analysis, 2025-2032
Pages: 160 | Base Year: 2024 | Release: June 2025 | Author: Versha V.
Psoriasis drugs are medications used to treat psoriasis, a chronic autoimmune skin condition that causes inflammation, redness, and scaling. The market includes a range of therapies such as biologics, topical agents, and systemic treatments aimed at managing symptoms and preventing flare-ups.
These drugs are applied in clinical and home settings to improve skin health, reduce inflammation, and enhance the quality of life for individuals affected by moderate to severe psoriasis.
The global psoriasis drugs market size was valued at USD 19.39 billion in 2024 and is projected to grow from USD 21.15 billion in 2025 to USD 40.96 billion by 2032, exhibiting a CAGR of 9.68% during the forecast period.
The growth of the market is driven by a rising geriatric population and increasing demand for long-term, safe treatments tailored to age-related immune decline. Additionally, Innovation in biologics targeting advanced pathways is shaping the long-term management of chronic, resistant cases.
Major companies operating in the psoriasis drugs industry are Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB S.A., AbbVie, Merck & Co., Inc., Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals UK Limited, Pfizer Inc., LEO Pharma A/S, Sun Pharmaceutical Industries Limited, Arcutis Biotherapeutics, Inc, Biogen, Bristol-Myers Squibb Company, and Sanofi.
The market is driven by the rising global prevalence of psoriasis, which is increasing the demand for effective and accessible treatment options. With increasing prevalence rates in regions like Asia, Europe, and the Middle East, the expanding patient pool is prompting healthcare providers to prioritize dermatological care.
This growth is compelling pharmaceutical companies to invest in innovative therapies, expand geographic reach, and enhance patient engagement strategies to meet the evolving treatment needs of a diverse global population.
Market Driver
Growing Geriatric Population
The psoriasis drugs market is driven by the increasing geriatric population, which is more susceptible to immune-mediated disorders such as psoriasis. Age-related decline in immune function leads to prolonged disease activity and more frequent flare-ups in older adults. This rising patient segment is creating greater demand for safe, long-term treatment options tailored to their health needs.
As the global elderly population expands, the market is experiencing increased pressure to provide therapies that address both efficacy and comorbidity management in aging individuals.
Market Challenge
Limited Long-Term Efficacy and Relapse Risk
The psoriasis drugs market faces a significant challenge due to limited long-term efficacy and the risk of disease relapse. Many existing therapies, especially topical and systemic drugs, provide temporary relief but fail to sustain long-term disease control. Patients often experience symptom recurrence after treatment discontinuation, impacting quality of life and treatment satisfaction.
To address this, companies are investing in next-generation biologics and small molecule inhibitors with extended durability and fewer side effects. Clinical research is increasingly focused on achieving long-lasting immune modulation, while firms are also exploring maintenance dosing strategies and personalized treatment plans to enhance long-term disease management and reduce relapse rates.
Market Trend
Advancements in Biologic Therapies
A key trend shaping the psoriasis drugs market is the continued development of biologic therapies that target specific immune pathways. These treatments offer improved outcomes for patients with moderate to severe psoriasis, especially those unresponsive to conventional options. Biologics provide durable skin clearance with favorable safety profiles, supporting their growing adoption for long-term disease management.
Segmentation |
Details |
By Class |
Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, Others |
By Treatment |
Topical, Systemic, Biologics |
By Route of Administration |
Oral, Parenteral |
By Region |
North America: U.S., Canada, Mexico |
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
South America: Brazil, Argentina, Rest of South America |
Market Segmentation:
Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
North America psoriasis drugs market share stood at 34.09% in 2024 in the global market, with a valuation of USD 6.61 billion. The region dominates the market due to its strong clinical research ecosystem and rapid regulatory approvals. Moreover, a well-established framework for conducting pediatric and adult clinical trials is accelerating data generation and supporting early therapeutic validation.
In addition, regulatory bodies in this region enable timely review and approval of advanced treatments, ensuring swift access to underserved populations. This integrated approach strengthens North America's leadership in delivering innovative, evidence-based psoriasis therapies across diverse patient groups, thereby driving market growth in this region.
Asia Pacific psoriasis drugs industry is poised for significant growth at a robust CAGR of 10.70% over the forecast period. The growth of the market in Asia Pacific is driven by improved healthcare infrastructure, which is enhancing access to dermatological care and advanced treatments. The expansion of hospitals, clinics, and specialized dermatology centers is enabling timely diagnosis and effective disease management.
Governments and private sectors are investing in healthcare modernization, particularly in emerging economies, to bridge urban-rural gaps. This advancement is facilitating the wider availability of biologics and systemic therapies, driving increased treatment adoption across diverse patient populations in the region.
Companies in the psoriasis drugs industry are actively pursuing strategic initiatives such as mergers and acquisitions, product launches, and collaborative agreements to strengthen their market position. Key players are expanding their portfolios through biosimilar introductions, targeting underserved patient segments, and entering high-growth regions.
Continuous investments in late-stage clinical pipelines and regulatory filings further reflect their commitment to accelerating commercialization timelines and reinforcing their competitive edge in a rapidly evolving therapeutic landscape.
Recent Developments (Product Launch)